Brain Cancer

Results from a phase II clinical trial with HSPPC-96 (vitespen), an autologous heat shock protein-peptide vaccine, have shown promise in patients with recurrent glioblastoma multiforme.

Hypofractionated stereotactic radiotherapy (SRT) appears to be safe and effective in preventing recurrence at resection cavities following surgical resection of brain metastasis and may spare many patients from whole brain radiotherapy (WBRT) and its adverse effects.

Researchers have reported cases of brain tumors among cardiologists and radiologists that work in cardiac catheterization laboratories. In addition to support from the literature, documenting 5 cases of brain tumors, a new study reports 4 new cases of brain malignancies, all in the left hemisphere of the brain.

The US Food and Drug Administration (FDA) has approved a portable noninvasive device, worn on the head, to treat adults whose glioblastoma multiforme (GBM) recurs or progresses following chemotherapy and radiation therapy.

The odds are exceedingly slim that you'll ever see an intracranial MPNST. With no established treatments and tough clinical dilemmas, you don't want to. But 3 recent case reviews and new insights from biology suggest this rare tumor may finally be vulnerable.

Typically glioblastoma patients are dead within 15 months of diagnosis, no matter how complete and well-planned their therapy.

The Ivy Glioblastoma Atlas Project will track genetic mutations in glioblastoma multiforme and produce a free, online medical atlas. The Seattle-based project is a partnership between the Ben and Catherine Ivy Foundation, the Allen Institute for Brain Science, and the Ben and Catherine Ivy Center for Advanced Brain Tumor Treatment at the Swedish Neuroscience Institute.

In July 2009, the US Food and Drug Administration (FDA) granted approval for use of the vascular endothelial growth factor (VEGF) inhibitor bevacizumab (Avastin) in combination with interferon alfa for treatment of patients with metastatic renal cell carcinoma (RCC).

Adult survivors of childhood craniopharyngiomas, the second most common type of childhood brain tumor, face many challenges, including multiple life-threatening metabolic abnormalities. Serious metabolic deficits can result from injury to the pituitary gland or hypothalamus.

The development of metastatic disease in patients with paraganglioma is an unusual and challenging event. This case report and review describes the specific features of this disease and the multiple therapeutic options.

Despite the high prevalence of brain metastases in patients with metastatic lung cancer, these patients have been excluded from enrollment in clinical trials of new therapeutic drugs. The reasons for exclusion have centered on concerns that the blood-brain barrier may impede drug delivery into brain metastases, that brain metastases confer a dismal survival for metastatic lung cancer patients, and that brain metastases carry risk for cerebrovascular hemorrhage. A focused, updated review of these issues, however, clearly shows that these particular concerns are unwarranted. An extensive review of clinical trials on the efficacy of chemotheraputic agents against lung cancer brain metastases is also provided. This collective information describes an area in need of therapeutic development and supports an initiative to evaluate novel targeted therapies for lung cancer brain metastases.

With the combination of radiation therapy and temozolomide (Temodar), some patients with glioblastoma multiforme are now surviving more than 4 years, according to updated results from a randomized phase III trial

Encouraging Avastin results in glioblastoma multiforme

Data for the investigational agent cediranib (AZD2171) were presented at the annual meeting of the American Society of Clinical Oncology (ASCO) from a phase II monotherapy study in patients with recurrent glioblastoma, the most aggressive form of primary brain tumor, with a high unmet medical need.

Swiss drug regulators have become the first to approve Novartis' Tasigna (nilotinib) for the treatment of patients with Ph+ chronic myeloid leukemia who are resistant or intolerant to imatinib (Gleevec)

In the June issue of ONCOLOGY, authors McGregor et al did an admirable job of reviewing childhood cancer advances and current issues in their article entitled "Pediatric Cancers in the New Millennium: Dramatic Progress, New Challenges"

The oral multitargeted tyrosine kinase inhibitor cediranib (Recentin, AstraZeneca), known experimentally as AZD2171, alleviated edema and showed an improvement in progression-free survival, compared with historical controls, in a phase II study of patients with recurrent glioblastoma

The third-generation epothilone KOS-1803 may optimize tumor penetration while limiting exposure to other tissues

Radioimmunotherapy (RIT) with a radiolabeled monoclonal antibody 131I-8H9, delivered intrathecally, appears to have clinical utility when added to salvage therapy for patients with metastatic cancer to the central nervous system (CNS), according to a phase I study reported at the 2007 American Association of Cancer Research annual meeting (LB-4).

Celldex Therapeutics has initiated a multicenter phase II/III trial of its brain tumor vaccine CDX-110 in patients with newly diagnosed glioblastoma multiforme (GBM) that expresses EGFRvIII, a variant of EGFR not present in normal tissue.

Metastatic lesions to the brain occur commonly in oncology patients and portend a very poor outcome, as they often occur in the setting of progressive systemic metastatic disease and can result in neurologic deterioration that may preclude therapy. Therapy of patients with brain metastases requires a combination of measures to achieve local control at the site of metastasis (eg, with surgical resection or radiosurgery) and to reduce the subsequent risk of recurrences elsewhere in the brain (eg, with whole-brain radiation). Successful therapy of extracranial systemic metastases is required for optimal outcomes. Clinical trials are currently underway to define the optimal role of whole-brain radiation and radiosurgery in different subsets of patients. Novel therapies to enhance radiation responsiveness are also under investigation. In the current review, we discuss recent developments in the management of patients with brain metastases.

Metastatic lesions to the brain occur commonly in oncology patients and portend a very poor outcome, as they often occur in the setting of progressive systemic metastatic disease and can result in neurologic deterioration that may preclude therapy. Therapy of patients with brain metastases requires a combination of measures to achieve local control at the site of metastasis (eg, with surgical resection or radiosurgery) and to reduce the subsequent risk of recurrences elsewhere in the brain (eg, with whole-brain radiation). Successful therapy of extracranial systemic metastases is required for optimal outcomes. Clinical trials are currently underway to define the optimal role of whole-brain radiation and radiosurgery in different subsets of patients. Novel therapies to enhance radiation responsiveness are also under investigation. In the current review, we discuss recent developments in the management of patients with brain metastases.

Therapy of patients with brain metastases requires a combination of measures to achieve local control at the site of metastasis and to reduce the subsequent risk of recurrences elsewhere in the brain. In the current review, we discuss recent developments in the management of patients with brain metastases.

The National Cancer Institute (NCI) recently awarded The University of Texas M.D. Anderson Cancer Center $11 million to lead the largest genetic study ever conducted on the causes and risk factors of adult and pediatric gliomas. Melissa Bondy, PhD, professor of epidemiology and director of the Childhood Cancer Epidemiology and Prevention Center, is principal investigators of the "Gliogene" study.

A device that displays a holograph-like 3-dimensional (3D) image, created from a CT, MRI, or PET dataset, holds promise for more accurate radiotherapy treatment planning (see image on page 1). James C. H. Chu, PhD, professor of radiation oncology, Rush University Medical Center, presented results of a pilot study of the Perspecta Spatial 3D System, developed by Actuality Systems, Inc. (Bedford, Massachusetts), at the 48th Annual Meeting of the American Society for Therapeutic Radiology and Oncology